AUS
NZ
UK
CA
USA
IND
Highlights
- Recce Pharmaceuticals (RCE) receives approval for a Phase 3 trial in Indonesia targeting diabetic foot infections.
- Indonesia's rising diabetes rates make it a strategic location for Recce's innovative treatment.
- The trial builds on the company's history of promising results with R327 in bacterial infection treatment.
Recce Pharmaceuticals (ASX:RCE), a Sydney-based biotech, has achieved a significant milestone by securing approval for its Registrational Phase 3 trial in Indonesia. This pivotal study will evaluate its topical gel, RECCE 327 (R327G), designed to treat diabetic foot infections (DFIs). Approval from Indonesia's National Agency of Drug and Food Control (Badan POM) and the ethics committee marks a critical step forward, with patient dosing expected to commence shortly.
This initiative aligns with Recce's objective of global expansion and marks its first such trial in Indonesia, a region heavily impacted by diabetes.
Indonesia’s Growing Diabetes Epidemic
Indonesia faces a pressing health challenge as diabetes rates continue to climb. According to the International Diabetes Federation, over 10% of the Indonesian population was diagnosed with diabetes as of 2021, and projections indicate further growth in the coming years. Alarmingly, a majority of cases remain undiagnosed, leaving millions vulnerable to complications such as DFIs. These infections, a common consequence of untreated diabetes, are a leading cause of nontraumatic foot amputations globally.
Given this context, Indonesia represents a critical opportunity for advancing treatment solutions. The trial, one of the largest DFI studies worldwide, holds significant potential to address this unmet need.
Tackling Diabetic Foot Infections
DFIs are a severe complication for diabetes patients, often resulting from polymicrobial infections involving pathogens such as S. aureus and E. coli. R327G, Recce’s proprietary anti-infective candidate, aims to provide an effective treatment alternative. Previous preclinical and early-stage clinical studies have demonstrated its efficacy in combating infections, including those caused by antibiotic-resistant bacteria like MRSA.
Towards Commercialisation
This Phase 3 trial is a pivotal step in Recce’s broader plan for commercialisation. The company has already shown success with R327 in treating burns, wounds, and other bacterial infections through earlier trials. The Indonesian study builds on these foundations, showcasing Recce’s commitment to addressing global health challenges.
The trial also aligns with Indonesia’s healthcare priorities. Badan POM officials have expressed their support for innovative solutions like R327G to tackle critical health issues such as DFIs.
With its strategic expansion into Indonesia, Recce Pharmaceuticals is advancing towards its goal of developing impactful treatments for infectious diseases and exploring broader commercial opportunities.
